A balanced multicentric control cohort of newly diagnosed MGMT promoter methylated glioblastoma patients, uniformly treated under real‐life conditions with maximum‐safe surgical resection, radiotherapy, and temozolomide according to the EORTC‐NCIC‐26981‐22981/CE.3 trial served as a comparison [21]. This evidence concerns the gene MGMT and glioblastoma.